How will moving toward outcome-based payment models affect financing in MedTech?

Moving toward value-based care models, MedTech companies have seen increasing price pressures and the necessity to improve patient outcomes. When it comes to demonstrate the improvements in patient outcomes, it may prove longer for a company to see significant financial return. How are the new outcome-based payment models changing the way innovation is perceived? How is quality measured and how are investment criteria evolving? Who takes on risk in a value-based care model? How to ensure improved communication within the payers‘ community to ease funding and reimbursement?